VANDA PHARMACEUTICALS INC. Finite-Lived Intangible Asset, Expected Amortization, Year Four
VANDA PHARMACEUTICALS INC. (VNDA) had Finite-Lived Intangible Asset, Expected Amortization, Year Four of $7.95 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Four $7.95M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $7.95M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $7.95M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Four $7.01M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Four |
|---|---|
| 2026-06-30 | $7.95M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.95M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $7.95M 10-K · filed 2026-02-12 |
| 2025-09-30 | $7.01M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $7.01M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $7.01M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $7.01M 10-K · filed 2025-02-14 |
| 2024-09-30 | $7.01M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $7.01M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $7.01M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $10.20M 10-K · filed 2024-02-08 |
| 2016-09-30 | $1.72M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $1.72M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $1.72M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $1.72M 10-K · filed 2016-02-12 |
| 2015-09-30 | $1.72M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $1.72M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $1.72M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $411.00K 10-K · filed 2015-03-13 |
| 2014-09-30 | $411.00K 10-Q · filed 2014-10-27 |
| 2014-06-30 | $411.00K 10-Q · filed 2014-08-08 |
| 2014-03-31 | $897.00K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $552.00K 10-K · filed 2014-02-25 |
| 2013-09-30 | $1.50M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $1.50M 10-Q · filed 2013-07-31 |
| 2013-03-31 | $1.50M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $1.50M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |